RnR Market Research

Nonmelanomatous Skin Cancer Pipeline Review H1 2015 Research Report Available at RnRMarketResearch.com

RnRMarketResearch.com adds “Nonmelanomatous Skin Cancer – Pipeline Review, H1 2015” to its store. This report provides an overview of the Nonmelanomatous Skin Cancer’s therapeutic pipeline.

 

Dallas, TX -- (SBWIRE) -- 06/09/2015 -- The report "Nonmelanomatous Skin Cancer – Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Nonmelanomatous Skin Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Nonmelanomatous Skin Cancer and special features on late-stage and discontinued projects.

Complete report on Nonmelanomatous Skin Cancer with 21 market data tables and 14 figures, spread across 44 pages is available at http://www.rnrmarketresearch.com/nonmelanomatous-skin-cancer-pipeline-review-h1-2015-market-report.html

Companies discussed in this Nonmelanomatous Skin Cancer – Pipeline Review, H1 2015 report include Advancell, EcoBiotics Limited, LEO Pharma A/S, Spherium Biomed S.L.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Drug Profiles mentioned in this report are ANs-40, ANS-401, ANS-403, EBC-46, OXT-328, Recombinant Peptide for Dermatology, Immunology and Oncology, Small Molecules to Activate Protein Kinase C for Dermatology and Cancer, Small Molecules to Inhibit PLK1 for Cutaneous Squamous Cell Carcinoma, SP-12054, Vaccine for HPV Associated Skin Cancer.

Order a purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=388751
(This is a premium report priced at US$2000 for a single user License.)

List of Tables
Number of Products under Development for Nonmelanomatous Skin Cancer, H1 2015 7
Number of Products under Development for Nonmelanomatous Skin Cancer - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Number of Products under Investigation by Universities/Institutes, H1 2015 10
Comparative Analysis by Clinical Stage Development, H1 2015 11
Comparative Analysis by Early Stage Development, H1 2015 12
Comparative Analysis by Unknown Stage Development, H1 2015 13
Products under Development by Companies, H1 2015 14
Products under Investigation by Universities/Institutes, H1 2015 15
Nonmelanomatous Skin Cancer - Pipeline by Advancell, H1 2015 16
Nonmelanomatous Skin Cancer - Pipeline by EcoBiotics Limited, H1 2015 17
Nonmelanomatous Skin Cancer - Pipeline by LEO Pharma A/S, H1 2015 18
Nonmelanomatous Skin Cancer - Pipeline by Spherium Biomed S.L., H1 2015 19
Assessment by Monotherapy Products, H1 2015 20
Number of Products by Stage and Target, H1 2015 22
Number of Products by Stage and Mechanism of Action, H1 2015 24
Number of Products by Stage and Route of Administration, H1 2015 26
Number of Products by Stage and Molecule Type, H1 2015 28
Nonmelanomatous Skin Cancer Therapeutics - Recent Pipeline Updates, H1 2015 40
Nonmelanomatous Skin Cancer - Dormant Projects, H1 2015 41
Nonmelanomatous Skin Cancer - Discontinued Products, H1 2015 42

List of Figures
Number of Products under Development for Nonmelanomatous Skin Cancer, H1 2015 7
Number of Products under Development for Nonmelanomatous Skin Cancer - Comparative Analysis, H1 2015 8
Number of Products under Development by Companies, H1 2015 9
Number of Products under Investigation by Universities/Institutes, H1 2015 10
Comparative Analysis by Early Stage Products, H1 2015 12
Assessment by Monotherapy Products, H1 2015 20
Number of Products by Top 10 Targets, H1 2015 21
Number of Products by Stage and Top 10 Targets, H1 2015 22
Number of Products by Top 10 Mechanism of Actions, H1 2015 23
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 24
Number of Products by Top 10 Routes of Administration, H1 2015 25
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 26
Number of Products by Top 10 Molecule Types, H1 2015 27
Number of Products by Stage and Top 10 Molecule Types, H1 2015 28

Explore more reports on cancer therapeutics at
http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/cancer-therapeutics

About RnRMarketResearch.com
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.